Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Oncology Vol 32 No 5

home / journals / oncology / oncology-vol-32-no-5
Advertisement

POINT: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer

POINT: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer

Pedro Isaacsson Velho, MD;Mario A. Eisenberger, MD
May 15th 2018
Article

Chemotherapy is the best option for the initial management of metastatic prostate cancer.


COUNTERPOINT: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer

COUNTERPOINT: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer

Robert J. Jones, MBChB, PhD
May 15th 2018
Article

Abiraterone has become the first-choice treatment for men with metastatic prostate cancer.


Implications of Mutation Profiling in Myeloid Malignancies-PART 2: Myeloproliferative Neoplasms and Other Myeloid Malignancies

Implications of Mutation Profiling in Myeloid Malignancies-PART 2: Myeloproliferative Neoplasms and Other Myeloid Malignancies

Kelsey Sokol, MD;Douglas Tremblay, MD;Sheena Bhalla, MD;Raajit Rampal, MD, PhD;John O. Mascarenhas, MD
May 15th 2018
Article

In this second part of our two-part review, we discuss the use of mutation profiling in the diagnosis, prognosis, and treatment of patients with myeloproliferative neoplasms and other myeloid diseases.


Robert Chapkin on Relationships Between the Gut Microbiome, Diet, and Colorectal Cancer

Robert Chapkin on Relationships Between the Gut Microbiome, Diet, and Colorectal Cancer

Robert S. Chapkin, MSc, PhD
May 15th 2018
Article

In this Q&A, we discuss the research into the relationships between gut microbiota, diet, and colorectal cancer.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.